Related Experiment Video
Updated: May 31, 2026

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
Published on: May 7, 2018
Glucagon-like peptide-1 gene therapy
Anne M Rowzee1, Niamh X Cawley, John A Chiorini
1Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, Bethesda, MD 20892-2190, USA.
Glucagon-like peptide 1 (GLP-1) and Exendin-4 are key peptides for managing type II diabetes. Research explores their cell biology, endocrine functions, and novel gene therapy applications targeting salivary glands.
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Glucagon-like peptide 1 (GLP-1) is an intestinal peptide hormone regulating glucose homeostasis.
- Exendin-4, a GLP-1 receptor agonist from Gila monster saliva, shares functional similarities with GLP-1.
- Both peptides are crucial for insulin secretion, glucagon inhibition, satiety, and gastric emptying.
Purpose of the Study:
- To review the cell biology of GLP-1 production and secretion from intestinal L-cells.
- To summarize the endocrine functions of GLP-1 and Exendin-4 in humans.
- To discuss gene therapeutic applications, particularly using salivary glands for diabetes treatment.
Main Methods:
- Literature review of cell biology, endocrine functions, and gene therapy.
- Analysis of GLP-1 and Exendin-4 mechanisms of action.
- Focus on recent advancements in salivary gland gene therapy for diabetes.
Main Results:
- GLP-1 and Exendin-4 exhibit significant therapeutic potential for type II diabetes.
- Intestinal L-cells are primary sites for GLP-1 production and secretion.
- Salivary gland gene therapy presents a promising novel approach for diabetes management.
Conclusions:
- GLP-1 and Exendin-4 are vital targets for type II diabetes adjunctive therapy.
- Understanding their cell biology and endocrine roles is critical for therapeutic development.
- Gene therapy utilizing salivary glands offers a innovative strategy for diabetes mellitus treatment.
More Related Videos
16:59Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
Published on: October 10, 2012
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Gene Therapy
Gene Therapy
Cell Specific Gene Expression
Hypoglycemia and Glucagon
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...